Literature DB >> 22302270

Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms.

Frances Austin1, Arun Mavanur, Magesh Sathaiah, Jennifer Steel, Diana Lenzner, Lekshmi Ramalingam, Matthew Holtzman, Steven Ahrendt, James Pingpank, Herbert J Zeh, David L Bartlett, Haroon A Choudry.   

Abstract

BACKGROUND: Peritoneal carcinomatosis (PC) in the setting of mucinous appendiceal neoplasms is characterized by the intraperitoneal accumulation of mucinous ascites and mucin-secreting epithelial cells that leads to progressive compression of intra-abdominal organs, morbidity, and eventual death. We assessed postoperative and oncologic outcomes after aggressive surgical management by experienced surgeons.
METHODS: We analyzed clinicopathologic, perioperative, and oncologic outcome data in 282 patients with PC from appendiceal adenocarcinomas between 2001 and 2010 from a prospective database. Kaplan–Meier survival curves and multivariate Cox-regression models were used to identify prognostic factors affecting oncologic outcomes.
RESULTS: Adequate cytoreduction was achieved in 82% of patients (completeness of cytoreduction score (CC)-0: 49%; CC-1: 33%). Median simplified peritoneal cancer index (SPCI), operative time, and estimated blood loss were 14 (range, 0–21), 483.5 min (range, 46–1,402), and 800 ml (range, 0–14,000), respectively. Pathology assessment demonstrated high-grade tumors in 36% of patients and lymph node involvement in 23% of patients. Major postoperative morbidity occurred in 70 (25%) patients. Median overall survival was 6.72 years (95% confidence interval (CI), 4.17 years not reached), with 5 year overall survival probability of 52.7% (95% CI, 42.4, 62%). In a multivariate Cox-regression model, tumor grade, age, preoperative SPCI and chemo-naïve status at surgery were joint significant predictors of overall survival. Tumor grade, postoperative CC-score, prior chemotherapy, and preoperative SPCI were joint significant predictors of time to progression.
CONCLUSIONS: Aggressive management of PC from mucinous appendiceal neoplasms, by experienced surgeons, to achieve complete cytoreduction provides long-term survival with low major morbidity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22302270      PMCID: PMC4100545          DOI: 10.1245/s10434-012-2241-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  22 in total

Review 1.  A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei.

Authors:  Tristan D Yan; Deborah Black; Renaldo Savady; Paul H Sugarbaker
Journal:  Ann Surg Oncol       Date:  2006-10-12       Impact factor: 5.344

2.  Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Robert M Smeenk; Vic J Verwaal; Ninja Antonini; Frans A N Zoetmulder
Journal:  Ann Surg       Date:  2007-01       Impact factor: 12.969

3.  Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms.

Authors:  T D Yan; M Links; Z Y Xu; P C Kam; D Glenn; D L Morris
Journal:  Br J Surg       Date:  2006-10       Impact factor: 6.939

4.  Analysis of loss of heterozygosity for tumor-suppressor genes can accurately classify and predict the clinical behavior of mucinous tumors arising from the appendix.

Authors:  Vivek Maheshwari; Allan Tsung; Yan Lin; Herb J Zeh; Sydney D Finkelstein; David L Bartlett
Journal:  Ann Surg Oncol       Date:  2006-09-29       Impact factor: 5.344

5.  Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases.

Authors:  Joseph Misdraji; Rhonda K Yantiss; Fiona M Graeme-Cook; Ulysses J Balis; Robert H Young
Journal:  Am J Surg Pathol       Date:  2003-08       Impact factor: 6.394

Review 6.  Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia.

Authors:  Olivier Glehen; Faheez Mohamed; François N Gilly
Journal:  Lancet Oncol       Date:  2004-04       Impact factor: 41.316

7.  Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).

Authors:  Dario Baratti; Shigeki Kusamura; Daisuke Nonaka; Martin Langer; Salvatore Andreola; Miriam Favaro; Cecilia Gavazzi; Barbara Laterza; Marcello Deraco
Journal:  Ann Surg Oncol       Date:  2007-11-28       Impact factor: 5.344

Review 8.  The intraoperative staging systems in the management of peritoneal surface malignancy.

Authors:  A Gomez Portilla; Kusamura Shigeki; Baratti Dario; Deraco Marcello
Journal:  J Surg Oncol       Date:  2008-09-15       Impact factor: 3.454

9.  Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center.

Authors:  Niraj J Gusani; Sung W Cho; Christos Colovos; Songwon Seo; Jan Franko; Scott D Richard; Robert P Edwards; Charles K Brown; Matthew P Holtzman; Herbert J Zeh; David L Bartlett
Journal:  Ann Surg Oncol       Date:  2007-12-12       Impact factor: 5.344

Review 10.  Surgical techniques in visceral resection and peritonectomy procedures.

Authors:  Philip Bao; David Bartlett
Journal:  Cancer J       Date:  2009 May-Jun       Impact factor: 3.360

View more
  18 in total

Review 1.  Surgical treatment of peritoneal carcinomatosis: current treatment modalities.

Authors:  Yakup Kulu; Beat Müller-Stich; Markus W Büchler; Alexis Ulrich
Journal:  Langenbecks Arch Surg       Date:  2013-11-19       Impact factor: 3.445

2.  FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma.

Authors:  Filippo Pietrantonio; Claudia Maggi; Giuseppe Fanetti; Roberto Iacovelli; Maria Di Bartolomeo; Francesca Ricchini; Marcello Deraco; Federica Perrone; Dario Baratti; Shigeki Kusamura; Elena Tamborini; Alessandra Castano; Paola Valentina Consonni; Ilaria Bossi; Cecilia Gavazzi; Massimo Milione; Giuseppe Pelosi; Filippo de Braud
Journal:  Oncologist       Date:  2014-06-20

3.  Depressive Symptoms in Patients Scheduled for Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery: Prospective Associations With Morbidity and Mortality.

Authors:  Carissa A Low; Dana H Bovbjerg; Steven Ahrendt; Sara Alhelo; Haroon Choudry; Matthew Holtzman; Heather L Jones; James F Pingpank; Lekshmi Ramalingam; Herbert J Zeh; Amer H Zureikat; David L Bartlett
Journal:  J Clin Oncol       Date:  2016-02-22       Impact factor: 44.544

4.  The use of carbon dioxide insufflation to facilitate identification of intestinal injuries in patients undergoing cytoreductive surgery and intraperitoneal chemotherapy.

Authors:  M A Kozman; O M Fisher; S J Valle; N Alzahrani; D L Morris
Journal:  Tech Coloproctol       Date:  2017-06-14       Impact factor: 3.781

5.  Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival.

Authors:  Joel M Baumgartner; Victoria M Raymond; Richard B Lanman; Lisa Tran; Kaitlyn J Kelly; Andrew M Lowy; Razelle Kurzrock
Journal:  Ann Surg Oncol       Date:  2018-06-14       Impact factor: 5.344

6.  A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion.

Authors:  Stephanie Downs-Canner; Ying Ding; Deepa R Magge; Heather Jones; Lekshmi Ramalingam; Amer Zureikat; Matthew Holtzman; Steven Ahrendt; James Pingpank; Herbert J Zeh; David L Bartlett; Haroon A Choudry
Journal:  Ann Surg Oncol       Date:  2014-10-28       Impact factor: 5.344

7.  Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer.

Authors:  Ryuma Tokunaga; Joanne Xiu; Curtis Johnston; Richard M Goldberg; Philip A Philip; Andreas Seeber; Madiha Naseem; Jae Ho Lo; Hiroyuki Arai; Francesca Battaglin; Alberto Puccini; Martin D Berger; Shivani Soni; Wu Zhang; Jimmy J Hwang; Anthony F Shields; John L Marshall; Hideo Baba; W Michael Korn; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2019-01-28       Impact factor: 12.531

8.  Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis.

Authors:  Deepa Magge; Mazen S Zenati; Frances Austin; Arun Mavanur; Magesh Sathaiah; Lekshmi Ramalingam; Heather Jones; Amer H Zureikat; Matthew Holtzman; Steven Ahrendt; James Pingpank; Herbert J Zeh; David L Bartlett; Haroon A Choudry
Journal:  Ann Surg Oncol       Date:  2013-12-10       Impact factor: 5.344

9.  Extensive cytoreductive surgery for appendiceal carcinomatosis: morbidity, mortality, and survival.

Authors:  Patrick L Wagner; Frances Austin; Ugwuji Maduekwe; Arun Mavanur; Lekshmi Ramalingam; Heather L Jones; Matthew P Holtzman; Steven A Ahrendt; Amer H Zureikat; James F Pingpank; Herbert J Zeh; David L Bartlett; Haroon A Choudry
Journal:  Ann Surg Oncol       Date:  2013-03-02       Impact factor: 5.344

10.  A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.

Authors:  Joel M Baumgartner; Thomas G Kwong; Grace L Ma; Karen Messer; Kaitlyn J Kelly; Andrew M Lowy
Journal:  Ann Surg Oncol       Date:  2015-12-17       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.